louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT07009769: AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy
Official title: Retrospective Clinical Study for Developing an AI-Driven Precision Diagnostic System for Lung Cancer Based on Liquid Biopsy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lung Cancer
Lead sponsor: Korea University Guro Hospital
Sponsor class: OTHER
First posted: 2025-06-08
Enrollment: 865
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Adult lung cancer patients (≥18 years old) and healthy controls, all South Korean nationals, with plasma collected before any cancer treatment.

Brief summary: The investigators aim to develop an AI-powered precision medicine system based on liquid biopsy that can comprehensively provide lung cancer patients with information on disease stage, histologic subtype, and presence of genetic mutations.


Eligibility criteria: Inclusion Criteria (Patients)

* Republic of Korea nationality
* Age ≥ 30 years
* Lung cancer based on radiologic and/or histopathologic examination
* No prior diagnosis of any other cancer and no history of anticancer treatment before the date of blood sample collection

Exclusion Criteria (Patients)

* History of other cancers before blood collection
* Prior cancer treatment before blood collection
* Incomplete clinical data
* No consent for sample use

Inclusion Criteria (Healthy Controls):

* Republic of Korea nationality
* No history of any cancer
* Age ≥ 30 years

Exclusion Criteria (Healthy Controls):

* History of any malignancy
* Incomplete clinical information or no consent for sample use

Primary outcomes:
measure: Diagnostic accuracy of the AI-based classification model using SERS signals from plasma-derived exosomes
timeFrame: Retrospective, based on pre-collected samples through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Guro-gu
country: Korea, Republic of
facility: Korea University Guro Hospital
state: Seoul
Study officials:
References:
Clinical trial NCT04141969: A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome
Official title: A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Post-Lyme Disease Syndrome (PLDS)
Keywords: Lyme
Lead sponsor: Optimal Health Research
Sponsor class: OTHER
First posted: 2019-10-28
Enrollment: 100
Sex: ALL
Minimum age (years): 12
Maximum age (years): 75
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will determine the effectiveness of a nutraceutical in treating the lingering effects of Lyme Disease after antibiotic treatment.

Detailed description: A Novel Nutraceutical to Combat Post-Lyme Disease Syndrome will be evaluated during a double blind, placebo controlled study. This study is an expansion of RLP042019 NCT04078841 Treating Post-Lyme Disease Syndrome With Acetogenins

Eligibility criteria: Inclusion Criteria:

1. A positive two-test methodology using a sensitive enzyme immunoassay (EIA) or immunofluorescence assay as a first test, followed by a western immunoblot assay for specimens yielding positive or equivocal results for Lyme Disease that has been treated with antibiotics but the symptoms persist post treatment.
2. Must be able to swallow a mixed powder drink.

Exclusion Criteria:

1 .Non Positive Western Blot test.

2. Positive Western Blot test where the individual has not been treated with antibiotics.

-

Primary outcomes:
measure: PROMIS Global-10
timeFrame: 6 months
measure: IHT Blood Test Assessment
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Salt Lake City
country: United States
facility: Optimal Health Research
state: Utah
Study officials:
affiliation: Optimal Health Research
name: Dr Osguthorpe, ND
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00563069: Premedication With Oral Midazolam in Patients Undergoing Rigid Cystoscopy: A Randomized, Double-blind, Placebo-controlled Trial
Official title: Premedication With Oral Midazolam in Patients Undergoing Rigid Cystoscopy: A Randomized, Double-blind, Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cystoscopy
Keywords: diagnostic and therapeutic rigid cystoscopy
Lead sponsor: Hospital Authority, Hong Kong
Sponsor class: OTHER_GOV
Collaborators: name: Chinese University of Hong Kong
First posted: 2007-11-26
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: To investigate the efficacy of oral midazolam for patients undergoing rigid cystoscopy in:

1. relieving patient's anxiety and improving satisfaction
2. reducing procedure-related pain
3. facilitating the diagnostic and therapeutic interventions during rigid cystoscopy


Eligibility criteria: Inclusion Criteria:

* Elective rigid cystoscopy
* Either diagnostic or therapeutic
* Age between 18 to 80

Exclusion Criteria:

* Patients with allergy to midazolam or other benzodiazepine groups
* Pregnancy
* Emergency rigid cystoscopy
* ASA class 3 or above
* Patients on psychiatric medications
* Alcoholics

Primary outcomes:
measure: Pain score during the procedure as assessed by visual analog scale
Secondary outcomes:
measure: Patient's satisfaction
measure: Patient's willingness to repeat the procedure
measure: Patient's cooperativeness during the procedure as assessed by surgeons
Other outcomes:
Locations:
city: Hong Kong
country: China
facility: Department of Surgery, Prince of Wales Hospital
Study officials:
affiliation: Department of Surgery, Prince of Wales Hospital/ The Chinese Univerisity of Hong Kong
name: Shirley YW Liu, Dr
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01642069: Studying Genes in Samples From Younger Patients With Acute Megakaryoblastic Leukemia
Official title: Observational - NUP98/JARID1A as a Recurrent Aberration in Pediatric Acute Megakaryoblastic Leukemia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Childhood Acute Megakaryocytic Leukemia (M7)
Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies
Lead sponsor: Children's Oncology Group
Sponsor class: NETWORK
Collaborators: name: National Cancer Institute (NCI)
First posted: 2012-07-17
Enrollment: 100
Sex: ALL
Maximum age (years): 30
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with acute megakaryoblastic leukemia.

Brief summary: This laboratory study is looking into genes in samples from younger patients with acute megakaryoblastic leukemia (AMKL). Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in RNA and identify biomarkers related to cancer

Detailed description: Study Subtype: Ancillary/Correlative Observational Study Model: Cohort Time Perspective: Retrospective Biospecimen Retention: Samples With DNA Biospecimen Description: Cryopreserved mRNA Study Population Description: Samples from AAML0531 Sampling Method: Non-Probability Sample

OBJECTIVES:

I. To determine whether NUP98/JARID1A expression is a recurrent translocation in NUP98-rearranged cases in pediatric acute megakaryoblastic leukemia (AMKL).

II. To screen the Children Oncology Group (COG) samples for genetic aberrations in pediatric AMKL.

OUTLINE:

Cryopreserved specimens are analyzed for NUP98 fusion to NSD1, JARID1A, and TOP1, myeloid/lymphoid or mixed-lineage leukemia (MLL)-rearrangements, and other gene expression profiling by reverse transcriptase polymerase chain reaction (RT-PCR) and karyotyping or fluorescence in situ hybridization (FISH). Results are then compared with each patient's outcome data.

Eligibility criteria: Inclusion Criteria:

* Cryopreserved specimens of pediatric patients diagnosed with acute megakaryoblastic leukemia

Primary outcomes:
measure: Complete remission (CR, defined as less than 5% blasts in the bone marrow, with regeneration of tri-lineage hematopoiesis, plus absence of leukemic cells in the cerebrospinal fluid or elsewhere)
timeFrame: Up to 8 weeks
measure: Probability of event-free survival (pEFS, defined as time between diagnosis and first event, including non-remitting, death of any cause and second malignancy)
timeFrame: Up to 8 weeks
measure: Overall survival (pOS, defined as time between diagnosis and death)
timeFrame: Up to 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Monrovia
country: United States
facility: Children's Oncology Group
state: California
Study officials:
affiliation: Children's Oncology Group
name: Soheil Meshinchi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05504369: Effects of Magnetic Tape on the Autonomic Nervous System
Official title: Effects of Magnetic Tape on the Autonomic Nervous System
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain
Keywords: Magnetic tape
magnetic nano particles
Pupillometry
Autonomic nervous system
lower back pain
PA test
Skin pinch test
Lead sponsor: Florida Gulf Coast University
Sponsor class: OTHER
Collaborators: name: University of Valencia
First posted: 2022-08-17
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Single group design with random allocation of intervention placebo versus treatment tape. Next day other intervention was used
Primary purpose: BASIC_SCIENCE

Brief summary: The effect of magnetic tape on pain and autonomic nervous system in subject with lower back pain.

Detailed description: The effects of magnetic nanoparticles in tape applied in the lumbar spine on the autonomic nervous system measured with fully automated pupillometry and on pain in the spine measured with posterior to anterior pressure on the spinous process and the skin pinch test paravertebrally

Eligibility criteria: Inclusion Criteria:

* Current lower back pain with NPRS of 5
* Between ages 18-65

Exclusion Criteria:

* No lower back pain or pain \<5 on the NPRS
* Not meeting age limit
* Having condition that prevents the PA procedure
* Conditions of the nervous system and inability keep eyes open

Primary outcomes:
measure: Pupillometry
timeFrame: 60 seconds measure preceding tape application. After outcome 5
measure: Pupillometry
timeFrame: Second 60 second measure immediate after tape application. After outcome 1
measure: Pupillometry
timeFrame: Third 60 measure 3 minutes after the tape is removed. After outcome 2
Secondary outcomes:
measure: PA spine
timeFrame: First PA measure of 5 seconds on each PA of 5 seconds on each segment is starting off the measurement phase. This is the first outcome measure
measure: Skin pinch test
timeFrame: 3 seconds skin pinch test at each level starting immediately following the first PA measure. After Outcome 4
measure: PA spine
timeFrame: Five second measure of PA of 5 seconds each segment is taken immediately after the third pupillometry measure (tape removed). After outcome 3
measure: Skin Pinch test
timeFrame: 3 seconds skin pinch test at each level starting immediately following outcome 6
Other outcomes:
Locations:
city: Valencia De Alcántara
country: Spain
facility: University of Valencia
Study officials:
References:
Clinical trial NCT00561769: Luteal Phase Commencing of Growth Hormone
Official title: Growth Hormone co-Treatment Within a GnRH Agonist Long Protocol in Patients With Poor Ovarian Response
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Infertility
Keywords: poor responder
growth hormone
luteal
Lead sponsor: Gulhane School of Medicine
Sponsor class: OTHER
Collaborators: name: Ren-Tıp ART Center, Bursa, Turkey
First posted: 2007-11-21
Enrollment: 61
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: poor response to previous COH in the same center

Brief summary: Commencing of growth hormone in luteal phase when follicular cohort for the next cycle is being gathered may increase mature oocytes in poor responder


Eligibility criteria: Inclusion Criteria:

* Poor responder

Exclusion Criteria:

* FSH \>20 IU

Primary outcomes:
measure: mature oocyte number
timeFrame: 2 years
Secondary outcomes:
measure: pregnancy rate
timeFrame: 2 years
Other outcomes:
Locations:
city: Bursa
country: Turkey
facility: Ren Tıp ART Center
Study officials:
affiliation: GATA Ankara
name: Tansu Kucuk, Assoc Prof
role: STUDY_DIRECTOR
References:
Clinical trial NCT00776269: Comparison of Argon Laser and Radiofrequency in Trichiasis Treatment
Official title: Comparison the Result of Argon Laser and Radiofrequency in Trichiasis Treatment of Patients Referred to Labbafinejad Oculoplastic Clinic
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Trichiasis
Keywords: Argon laser
Trichiasis
Radiofrequency
Patients with trichiasis
Lead sponsor: Shahid Beheshti University of Medical Sciences
Sponsor class: OTHER
Collaborators: name: Ophtalmic Research Centre
First posted: 2008-10-21
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this clinical trial study,the investigators intend to compare two methods of trichiasis treatment.One by argon laser and the other by radiofrequency then compare the result of these procedures, especially, the investigators would like to compare which of these have less complications such as bleeding,pain,notch in the site of surgery and etc.


Eligibility criteria: Inclusion Criteria:

* All patients who came to labbafinejad oculoplastic clinic due to trichiasis

Exclusion Criteria:

* Having a history of entropion
* Any history of previous laser ,radiofrequency therapy or surgery
* More than 50% of the area is involved with trichiasis
* More than 10 eye lashes need to be treated

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Ophthalmic Research Center
Study officials:
References:
Clinical trial NCT01899469: Efficiency of Physiotherapy Treatments for Low Back Pain in Women.
Official title: Efficiency of Physiotherapy Treatments for Low Back Pain in Women.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Low Back Pain
Lead sponsor: University Rovira i Virgili
Sponsor class: OTHER
First posted: 2013-07-15
Enrollment: 96
Sex: FEMALE
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Aim: To evaluate and compare the effectiveness of a combined treatment of TENS or Elec-tromagnetic and Back School with the effectiveness of only the Back School treatment.

Design: Single-blind experimental prospective study of clinic intervention. Setting: Physiotherapy and Speech Therapy Unit at the Cambrils Slight Hospital. Spain.

Population: 96 women (50-85 years) with chronic low back pathology. Methods: Subjects were divided into three randomized groups: Back School (group 1), TENS with Back School (group 2), and Magnetic therapy with Back School (group 3). They have re-ceived 20 sessions of treatment. The intensity of pain (EVA Scale) and the quality of life (Oswestry Scale) were measured, at the beginning and at the end of the treatment and after three and six months. Anthropometric and physical activity variables were collected.


Eligibility criteria: Inclusion Criteria:

* Women between 50 and 85 years.
* Chronic LBP condition for at least three months ago.
* Patient's agreement by signing the consent.

Exclusion Criteria:

* Cardiac pacemaker carriers.
* Patients with parts of osteosynthesis and / or prostheses.
* Patients with a not well balanced medical condition.
* Patients with TENS at home and / or having completed physiotherapy during the last three months.
* Patients with skin infectious diseases or skin lesions and / or areas of hypoesthesia.
* Patients with malignant tumours.
* Patients who received any spinal injection during the last six weeks.
* Patients who participate or have participated in a study in the last three months

Primary outcomes:
measure: Pain was measured at the beginning and after the treatment with the Visual Scale Analogue (VAS)
timeFrame: 24 weeks
measure: Oswestry disability index (ODI)
timeFrame: 24 weeks
Secondary outcomes:
measure: Questionnaire of Physical Activity (ClassAF)
timeFrame: 4 weeks
Other outcomes:
measure: Body Mass Index (BMI)
timeFrame: 4 weeks
Locations:
city: Cambrils
country: Spain
facility: Hospital Lleuger de Cambrils
state: Tarragona
Study officials:
affiliation: University Rovira i Virgili
name: Ester Poblet, PT
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06544369: Prospective Study on COVID -19 Reinfection on Vaccinated and Non-vaccinated Outpatients
Official title: Prospective Study on COVID -19 Reinfection on Vaccinated and Non-vaccinated Outpatients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19 Pandemic
Lead sponsor: Deraya University
Sponsor class: OTHER
First posted: 2024-08-09
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: the study group are infected patients with COVID-19

Brief summary: the aim of the study is to compare the severity of symptoms in case of reinfection with COVID-19. the study will compare between two groups; vaccinated and non vaccinated. the side effects from vaccination and symptoms of infection and reinfection will be reprted.


Eligibility criteria: Inclusion Criteria:

* clinically diagnosed with COVID infection
* take any type of vaccines

Exclusion Criteria:

* no accept sharing
* not vaccinated with COVID vaccine

Primary outcomes:
measure: percent of reinfection with COVID-19 in vaccinated and non vaccinated
timeFrame: one year
Secondary outcomes:
measure: scoring of symptoms in case of reinfection in vaccinated and non vaccinated
timeFrame: one year
Other outcomes:
Locations:
city: Minya
country: Egypt
facility: Deraya university
Study officials:
References:
Clinical trial NCT05280769: Effects of an Oral Nicotine Product in Smokeless Tobacco Users
Official title: Effects of an Oral Nicotine Product in Smokeless Tobacco Users
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tobacco Use
Lead sponsor: Virginia Commonwealth University
Sponsor class: OTHER
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2022-03-15
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single arm study
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this research study is to find out how three different nicotine pouches and participant's own brand of smokeless tobacco affect blood nicotine levels and how participants feel.


Eligibility criteria: Inclusion Criteria:

* Healthy (determined by self-report)
* Between the ages of 18-55
* Willing to provide informed consent, attend the lab sessions and abstain from tobacco/nicotine as required
* Agree to use designated products according to study protocol
* Smokeless tobacco users and must report using smokeless tobacco daily. Smokeless tobacco users must have a 'positive' cotinine cassette result to verify nicotine use

Exclusion Criteria:

* The following self-reported current, diagnosed medical condition(s): heart-related conditions (e.g., recent heart attack/stroke, coronary heart disease), severe immune system disorders (e.g., HIV/AIDS, multiple sclerosis), respiratory disorders (e.g., COPD, asthma), kidney diseases, liver diseases (e.g., cirrhosis), or seizures
* Other self-reported current, diagnosed medical conditions (e.g., diabetes, thyroid disease, Lyme disease) may be excluded after consultation with the PI and medical monitor: any medical condition/medication that may affect participant safety, study outcomes, or biomarker data will be excluded based on these consultations
* Self-reported current, diagnosed psychiatric conditions, and who are currently under the care of a physician for psychiatric conditions, or who report current psychiatric treatment or psychotropic medication use
* Not providing answers to questions related to inclusion/exclusion criteria
* Breast-feeding or pregnant women (pregnancy tested by urinalysis at screening
* Weigh less than 110 pounds
* Intend to quit tobacco/nicotine use in the next 30 days

Primary outcomes:
measure: Change in Plasma nicotine concentration
timeFrame: Baseline to the end of the session, approximately 4 hours
Secondary outcomes:
Other outcomes:
measure: Change physical sensations
timeFrame: Baseline to the end of the session, approximately 4 hours
measure: Change in sensations and emotions
timeFrame: Baseline to the end of the session, approximately 4 hours
measure: Change emotions and urges
timeFrame: Baseline to the end of the session, approximately 4 hours
Locations:
city: Richmond
country: United States
facility: Virginia Commonwealth University
state: Virginia
Study officials:
affiliation: Virginia Commonwealth University
name: Alison Breland, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04115969: Outcome After Non-invasive Ventilation.
Official title: Outcome After Non-invasive Ventilation - an Observational Study at the Intensive Care Unit at Sundsvall Hospital.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Respiratory Insufficiency
Keywords: non-invasive ventilation
critical care
Lead sponsor: Västernorrland County Council, Sweden
Sponsor class: OTHER_GOV
First posted: 2019-10-04
Enrollment: 92
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admitted to Sundsvalls intensive care unit treated with non-invasive ventilation.

Brief summary: The study is an exploratory retrospective observational study with the aim to describe outcome fo the cohort of patients that receive non-invasive ventilation at an intensive care unit.

Main research questions are:

* Characteristics of the cohort.
* The course for the patients at the ICU.
* ICU-mortality and 30-day mortality
* Amount of patients with limitations of care.
* Factors associated with mortality.


Eligibility criteria: Inclusion Criteria:

* Patients treated with Non invasive ventilation
* Admitted to Sundsvalls ICU during 2018

Exclusion Criteria:

* Below 18 years age.

Primary outcomes:
measure: Patient characteristics
timeFrame: At the day of admission to the ICU - 1 day
measure: ICU-mortality
timeFrame: Patients will be followed during their ICU-stay - estimated to be 1 to 60 days.
measure: 30-day mortality
timeFrame: 30 days from admission to ICU
Secondary outcomes:
measure: Factors associated with mortality
timeFrame: 30 days from admission to ICU
Other outcomes:
Locations:
city: Sundsvall
country: Sweden
facility: Västernorrland County Council / Sundsvall Hospital
state: X
Study officials:
affiliation: Västernorrland county council (Region Västernorrland)
name: Erik Svensk, MD
role: PRINCIPAL_INVESTIGATOR
References: